Human Fc gamma RIIB/C (CD32b/c) Protein, His Tag (SPR & BLI & MALS verified)
分子別名(Synonym)
FCGR2B,C,CD32b,c,FcRII-b,c,Fc-gamma RII-b,c,Fc-gamma-RIIb,c,CD32,FCG2,IGFR2,CDw32
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CD32b/c, His Tag (CDB-H5228) is expressed from human 293 cells (HEK293). It contains AA Ala 46 - Pro 217 (Accession # P31994-1). In the region Ala 46 - Pro 217, the AA sequence of Fc gamma RIIB and Fc gamma RIIC are homologus.
Predicted N-terminus: Ala 46
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 20.4 kDa. The protein migrates as 28-31 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to different glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
背景(Background)
IgG(FcγR)Fc區(qū)的受體是Ig超家族的成員,其在激活或抑制免疫應(yīng)答中起作用。識(shí)別出三類人FcγR:RI(CD64),RII(CD32)和RIII(CD16),它們產(chǎn)生多種同種型。
人FcγRII/CD32有三個(gè)基因(A,B和C),小鼠FcγRII B有一個(gè)基因(CD32B)。低親和力免疫球蛋白γFc區(qū)受體II-b(FCGR2B)也稱為CD32b,FCG2,IGFR2。CD32B在B細(xì)胞和髓樣樹突狀細(xì)胞上表達(dá)。CD32B在B細(xì)胞上的連接下調(diào)抗體產(chǎn)生,并且在某些情況下可能促進(jìn)細(xì)胞凋亡。CD32B在樹突狀細(xì)胞上的共連接抑制成熟并阻斷細(xì)胞活化。CD32B也可能是單克隆抗體治療惡性腫瘤的靶標(biāo)。
關(guān)鍵字: CD32B;FCGR2B蛋白;CD32B重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。